Coronavirus Notebook: COVAX Exceeds Vaccine Funding Target, Canada OKs Mix-And-Match Dosing
In a sign of growing support for more equitable vaccine distribution, many donors have pledged either money or doses to lower-income economies. The World Health Organization has granted emergency use listing to another Chinese vaccine, and Russia’s Sputnik V is to be produced in Bahrain for the MENA region.
You may also be interested in...
The US obtained access to doses that it will donate to low- and low-middle-income countries, Merck & Co. is lining up government purchases of its Phase III drug, and Ocugen will submit a BLA in the US rather than pursue an EUA for Bharat's vaccine. Plus progress and setbacks for COVID-19 therapeutics.
India has waived the need for local clinical trials for COVID-19 vaccines already approved in certain other countries, while the WHO has added a Chinese vaccine to its emergency use list. Meanwhile, South Korea issues new guidance for local vaccine trials and Japan gives more money to COVAX.
A new procurement deal will add to the rollout of COVID-19 vaccines at global level. However, the leaders of the COVAX Facility say that by the end of June they will face a shortfall of 190 million doses, mainly because of the crisis in India, and are calling on wealthier countries to increase their donations.